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Rheumatoid arthritis (RA) is associated with increased cardiovascular risk. Treatment with tumor necrosis factor
(TNF)-inhibitors leads to about a 50% reduction in the first cardiovascular event. TNF-inhibitors could transiently
improve flow-mediated vasodilation and improve carotid intima-media thickness (ccIMT) during the treatment of
RA. Treatment with TNF-inhibitors is associated with an increased total cholesterol (TC) and HDL-cholesterol (HDLc)
level, without sustained change of the atherogenic index. The overall cancer risk in RA patients is comparable to
that of the general population, but patients with RA slightly more often have lymphomas and lung tumors, and less
often have colorectal and breast tumors in comparison to the general population. In randomized controlled trials
(RCT) TNF-inhibitors did not increase the risk of solid malignancies, except for non-melanoma skin cancer (risk
doubled compared to control treatment). Meta-analysis of registries and long-term extension studies showed no
increased risk for total malignancies as well as for non-melanoma skin cancer when comparing TNF-inhibitors and
the classical disease modifying anti-rheumatic drugs (DMARDs) treatment.
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Rheumatoid arthritis (RA) is associated with an approxi-
mately doubled cardiovascular risk that approaches that
of diabetes. There is accumulating evidence that biologics,
particularly TNF-inhibitors, reduce the cardiovascular risk
in RA [1,2]. This might be mediated through favorable ef-
fects on the vasculature and/or the lipid profile.
Another clinically important question is if, and to what
extent, biologics increase the cancer risk in RA. Since it
is well known that lymphomas and lung tumors are
more often present in RA patients, compared to the gen-
eral population, it is important to know whether treat-
ment with TNF-inhibitors increases the relative risk for
malignancies in patients with RA.TNF-inhibitors and cardiovascular risk
One of the first studies investigating the effect of TNF-
inhibitors on cardiovascular risk comes from Jacobsson
et al. in 2005 [1]. Treatment with TNF-inhibitors led to
a more than 50% reduction of first cardiovascular events.
In the following years the findings of Jacobsson et al.
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2014The British Society for Rheumatology Biologics Regis-
ter comprises RA patients with active disease treated
with TNF-inhibitors or DMARDs who are followed pro-
spectively [2]. Remarkably, in the 2007 publication of
this registry with almost 11,000 patients, there was no
significant difference between the two groups when loo-
king at incident myocardial infarction. However, when
comparing the myocardial infarction rate between re-
sponders and non-responders to TNF-inhibitors, there
was a more than 60% reduction in the rate of myocardial
infarctions in the responding patients.
Biologics and vascular function
Ultrasound-based techniques have been widely used
to detect arterial endothelial dysfunction, overt carotid
atherosclerosis and arterial stiffness by assessing flow-
mediated vasodilation (FMD), common carotid intima-
media thickness (ccIMT) and pulse-wave velocity (PWV)/
augmentation index (AIx), respectively [3]. TNF-inhibitors,
such as infliximab (IFX), etanercept (ETN) or adalimumab
(ADA) improved FMD in numerous studies [4]. Most of
these studies were short-term (12 to 36 weeks). At least in
two cohorts, the favorable effects of biologics on FMD
were transient, when endothelial dysfunction returned
post-treatment [5,6]. Controversies have been observed
with respect to ccIMT and stiffness assessments. Carotidtral Ltd. This is an Open Access article distributed under the terms of the
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of IFX treatment in established RA [7]. ADA also im-
proved ccIMT in an early RA cohort [8]. On the other
hand, no effects of biologics on ccIMT were observed
in either cohort [4]. Anti-TNF therapy improved PWV
but did not affect AIx in RA patients [4]. Thus, it is
still uncertain whether biologics improve vascular func-
tion in RA or not.
Biologics and lipid profile
Although nowadays there is convincing evidence that
treatment with TNF-inhibitors is associated with a re-
duced cardiovascular risk, some argue that TNF-blocking
therapy has adverse effects on the lipid profile that might
translate into an increased cardiovascular risk instead of a
decreased cardiovascular risk. As the literature appears
contradictory in this respect several meta-analyses have
been done. The first systematic review and meta-analysis
comprised 15 studies encompassing 766 RA patients ful-
filling the inclusion criteria [9]. This meta-analysis re-
vealed an increased total cholesterol (TC) level (maximum
increase of 10%), that leveled off after one year of therapy.
HDL-cholesterol (HDLc) increased significantly in the first
two to six weeks of therapy (maximum increase 7%) and
decreased slightly after fifteen weeks of therapy. Thus,
treatment with TNF-inhibitors has a considerable, albeit
transient, effect on TC and HDLc levels in RA patients.
There was no sustained improvement of the atherogenic
index. Hence, the favorable effect of TNF-alpha blocking
agents on the cardiovascular risk in RA is not mediated by
beneficial effects on lipid metabolism. It is important to
realize that the effects of biologics on lipids should be
assessed in the phase in which patients have low disease
activity in order to avoid the ‘lipid paradox’ [10].
Rheumatoid arthritis and malignancies
The overall cancer risk in RA is comparable with the
general population [11]. However, patients with RA more
often have lymphomas and lung tumors with standardized
incidence ratios of 2.1 and 1.6, respectively. It is important
to realize that the risk for lymphoma is dependent on the
disease activity, the higher the disease activity, the higher
the chance for lymphomas. In contrast, patients with RA
do have colorectal and breast tumors less often in com-
parison to the general population.
TNF-inhibitors and cancer risk
Important information comes from the meta-analysis
that was published at the end of 2010 following a re-
quest by the European Medicines Agency to the market
authorization holders of the TNF-inhibitors to conduct a
joint meta-analysis of their RCT-data [12]. A total of 74
trials with 22,000 patients either treated with adalimu-
mab, etanercept or infliximab were included. Thirty-oneof these studies were in RA and 43 in other indications.
In total there were 178 malignancies, 130 in the TNF-
inhibitors group and 48 in the controls. When exclud-
ing non-melanoma skin cancer, the relative risk was
about 1, indicating that TNF-inhibitors do not increase
the risk for solid malignancies. However, when only loo-
king at non-melanoma skin cancer, the risk is approxi-
mately doubled when comparing treatment with TNF-
inhibitors and control treatment. Obviously, this study
indicates that TNF-blockade does, in the short term, not
increase the risk for solid malignancies but obviously
long-term risk assessment requires observational studies
and registries.
A first meta-analysis of registries and long-term ex-
tension studies was published in 2012; after an extensive
literature search these investigators identified twelve re-
gistries and five long-term extension studies [13]. When
comparing TNF-inhibitors versus the classical DMARDs
this meta-analysis indicated no increased risk for total
malignancies or for non-melanoma skin cancer.Clinical consequences
As thus far the literature indicates no increased risk for
solid malignancies, screening and testing for solid ma-
lignancies is not necessary when administering TNF-
inhibitors. However, regular attention to the skin remains
necessary when giving TNF-inhibitors, as the risk for non-
melanoma skin cancer, particularly in combination with
methotrexate, is approximately doubled. In this respect, it
is also important to realize that a recent study indicated a
50% increased relative risk of invasive melanoma [14].
These authors indicate that given the small increase in ab-
solute risk, the overall risk-benefit balance of TNF inhibi-
tors remains favorable. However, in patients having an
elevated risk for melanoma development, these drugs
might be contraindicated.Conclusions
TNF-inhibitors reduce cardiovascular risk by about 50%.
With respect to malignancies, these drugs probably are
associated with an increased risk for non-melanoma and
melanoma skin cancer making regular skin inspection
necessary. The risk for solid malignancies appears not
to be increased. Presently, the effects of TNF-inhibitors
appear favorable both from a cardiovascular point of
view as well as from a safety point of view, particularly
when considering the substantial improvement in the
quality of life associated with the use of these agents.
However, as some of the evidence is still debatable,
long-term prospective studies are still needed (and actu-
ally ongoing) to determine the risk of cardiovascular
diseases and malignancies in biologic-treated arthritis
patients.
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